start friday product avail client
direct distribut list extern platform pleas reach leerink
repres would like receiv
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
medacorp event updat immuno-oncolog washington dc
regulatori event fda adcom joint psychopharmacolog drug drug
medic meet american colleg prosthodontist american pancreat associ
associ molecular patholog japan digest diseas week
minor updat abstract
bottom line abstract american societi hematolog publish
morn among publish abstract data imdz phase ii random
agonist dose plu keytruda vs studi follicular lymphoma fl patient
overal abstract provid increment improv updat plu keytruda combin
appear activ alon abstract data cut-off date imdz
provid updat trial recal imdz lead program
toll-lik receptor agonist activ innat adapt arm immun system
imdz recent updat compani develop focu decid move forward ug
dose omit low dose radiat treatment await clinic data valid imdz
develop strategi ug data expect societi immunotherapi cancer
continu view execut import part imdz stori reiter mp
roundtabl highlight price pressur competit pbm retail
bottom line follow hcit distribut roundtabl recent host new york
cautiou pharma suppli chain meet host two medacorp
panel focus pharma suppli chain first focus pharmaceut distribut
come away cautiou distributor price pressur competit seem
pick second panel focus pbm specialti pharmaci distributor
retail like come even pressur aggress retail rate narrow
network esrx mp price aggress like pressur pbm margin
distributor kol suggest relief price sell-sid discount sound
robust may lead on-going margin pressur
adj dilut ep continu oper
adjust ep exclud acquisit amort one-tim item exclud interest expens relat
aet transact exclud revenu earn aet deal
final cut new part drug bill overhaul telehealth
bottom line final cut reimburs new part drug begin
line propos rule addit lever price
propos releas last week reduc drug cost medicar part begin januari
new physician administ drug reimburs wholesal acquisit wac plu
versu plu previous three month part drug would reimburs averag sale price
asp wac tend exceed asp chang could lower pharmaceut spend
chang among idea float trump administr februari budget propos
recommend medpac also propos chang physician fee schedul improv
price transpar reduc paper work streamlin bill promot electron health record ehr
interoper propos also would reimburs telemedicin check-in assess
posit telemedicin firm op
bottom line releas solid increas bp preliminari rate
end stage renal diseas esrd freestand facil rate compar final rate
view rate increas posit dialysi provid mp nr fm nr
drive upsid revenu margin driver aug upgrad
rule includ sever technic chang esrd prospect payment pp includ
expans transit drug add-on payment adjust tdapa allow new renal dialysi
drug biolog jan regardless whether fit exist function categori
elig tdapa also propos chang reduc paperwork chang around qualiti
propos solid vs preliminari rate increas esrd freestand facil rate
compar final rate propos rate
propos expans tdapa allow new renal dialysi drug biolog jan
regardless whether fit exist function categori elig tdapa
aug upgrad avail follow link
factsheet avail follow link
guidanc beatabl growth runway long pt
 methodolog ev/sal multipl estim
bottom line share trade today deliv solid sale beat quarter top-lin
growth acceler bp q/q despit absorb summer season gener lower
procedur volum med-tech broadli tougher comp creat major intervent
cardiolog meet held quarter vs last year clear us impella adopt
momentum continu acceler like driven increas awar around high risk pci
expans cardiogen shock initi nation hospit particip
hospit end continu ramp germani japan hospit
current approv japan vs june februari acknowledg
share cheap even sell-off high believ current level
repres attract entri point long-term holder given believ monopoli
larg under-penetrated market ultim could prove multipl current size
long runway continu top-tier sale growth progress toward industry-high
oper margin like consist estim upsid importantli believ
compani like revis multi-year vision set analyst meet --
revenu current high risk pci cardiogen shock indic alon
oper margin -- compani clearli track ahead goal alreadi
oper margin push close sale next year base estim
reiter op pt pt
revenu dilut gaap ep
updat rev ahead view gocovri uptak expand
bottom line report market close thursday central nervou system drug develop
releas result ahead expect
select key financi metric track commerci develop pipelin progress revenu
bit view cost bit cash hand septemb
paid prescript compani gocovri launch januari drug grew sequenti
script per prescrib doctor grew sequenti well look
forward salesforc focu set intensifi movement disord center sourc
higher prescrib valid commun neurologist pipelin news compani
phase studi walk ms track full enrol expect
view result demonstr near-term execut long-term progress
revenu view cost forecast admss report
paid prescript gocovri continu grow well script per prescrib doctor higher sequenti
look forward gocovri salesforc focu set intensifi movement disord center
pipelin phase studi walking-impair ms track
report show near-term execut long-term progress
doubl pipelin obviou worthwhil pt
 methodolog dcf use wacc termin growth rate
bottom line manag go all-in invest success remain skeptic whether
new product opportun justifi invest off-set declin makena
franchis preliminari adjust ebitda number impli significantli higher spend
previous assum street believ neg stock reaction stem whether
up-front invest go asset lead appropri return futur point
see uncertainti around compani two key near-term growth opportun intrarosa sale
continu pressur high gross-to-net therefor wonder product ever take
vyleesi approv skeptic subcutan sq profil
meaning deter util believ could potenti signific opportun
howev still earli limit visibl manag abil acceler patient
enrol phase trial mention continu see downsid risk street
expect makena franchis face addit gener competit make
minim chang revenu project increas spend flow
outer year lower pt reiter mp
adjust non-gaap ep non-gaap ep calcul analyst includ contribut
cbr
sale
bottom line afternoon report sale y/i line
pre-announce revenu octob ahead us y/i street
time pre-announce revenu came y/i ou
y/i also rais sale guidanc
 lower adjust ebitda guidanc loss vs posit adjust ebitda
previous primarili driven legal cost invest relat china distributor transit
compani deliv solid double-digit growth ytd reason see slowdown
momentum across busi remaind year believ just-rais
guidanc -- suggest y/i growth -- like conserv fact see potenti
upsid guidanc driven continu train educ effort expand
train cours nurs fellow improv guidelin believ drive growth
acceler open busi go forward ramp adopt highli under-penetrated
market on-going roll pro-v flex-v product seemingli drove major
out-performance becom meaning contributor beyond view
new distributor china could drive intern growth acceler along
continu progress mi pipelin complet converg enrol give us confid
ultim consist double-digit top-lin grower medium-to-long term
turn ebitda profit next year b/ net proce recent complet
underwritten offer cash long-term debt exit abil draw
anoth credit revolv facil believ suffici cash take compani
pipelin continu progress
revenu non-gaap adjust dilut ep
book declin mu slow trubridg instal guid
bottom line announc mix result thursday revenu adj ep beat
estim though revenu quarter improv book declin y/i tax benefit
ad instal push manag highlight schedul
implement includ one net new instal rel guidanc sound
high good us note may push next year book
declin y/i due declin averag contract size declin book suspect
slowdown overal market consist mp result though manag
provid formal guidanc continu drive margin expans cost reduct effort
ep ahead quarter concern slowdown book instal
schedul seem optimist view adjust estim quarter pt move
implement pipelin sound robust optimist
book disappoint amid declin averag contract size
revenu present mm non-gaap report exclud acquir amort stock comp
expens transact cost
plug gap increas market oppti remain market
bottom line announc thursday acquir
consensu revenu believ acquisit plug import gap portfolio
expand overal market opportun ad long-read remov
competit overhang oxford nanopor bgi technolog acquisit open
door new market realiz yet long-read technolog follow path elast
demand cost per gb gigabas reduct potenti integr system
road could featur technolog believ stock react posit address
gap expand market opportun despit dilut like see near term
transact cash expect close
acquir complimentary/orthogon technolog plug major gap remain unfil far
increas market opportun get access expand applic base
address competit headwind long-read nanopor technolog short-read competit
emerg china
transact like dilut near term
see potenti complet sequenc solut longer term appli elast demand
short- long-read
anti-trust concern overlap technolog applic base two compani
bottom line believ sell-off miss new base margin expans
present buy opportun maintain op rate see md deep valu opportun
attract yield lower estim pt
reflect lower base revenu ebitda miss lower outlook driven
declin birth worst declin last year believ cross sell
neonat could acceler volum add upsid estim anesthesia
mix pressur remain though trend acceler increas manag contract
partial off-set pressur improv physician practic effici outlook
mm remain potenti addit save lower revenu
ebitda trajectori still estim bp margin expans bp
yield remain attract expect md near-term use repurchas share
activ accret tuck-in potenti divestitur meddata mm
ebitda multipl could acceler capit deploy lower ebitda estim
mm mm mm mm mm mm
reflect lower revenu base continu acceler oper effici
miss across revenu ebitda ep driven weak birth
guidanc consensu time report set lower bar achiev start
new cfo stephen farber tenur
margin expans outlook remain track deliv mm improv physician
practic effici new cfo highlight opportun addit save
headwind birth declin appear transient volum upsid could come cross-sel
women children servic expans radiolog practic
payor mix anesthesia remain challeng partial off-set manag care contract
increas rang
lower estim reflect lower revenu ebitda base though
maintain bp margin expans bp
yield remain attract expect md near-term use repurchas
share activ accret tuck-in
initi sell meddata md manag servic organ could unlock valu fund share
repurchas debt paydown gener mm multipl
maintain op rate lower pt reflect lower base
revenu mil dilut ep
result disappoint book weak continu pt
bottom line allscript report disappoint result thursday afternoon though
adj ep line estim adj ep miss consensu revenu book
miss estim consensu book substanti quarter
y/i share count drove ep meet rel model amount adjust
high usual though book disappoint quarter backlog y/i
though suspect ei acquisit may driven much growth ei close
manag provid updat sale process netsmart explain
late stage follow expans becom complex process given non-control
interest uniqu jv structur call manag maintain guidanc guid
low-end prior rang item sound see success
cross-sel effort sound life scienc payer group continu grow believ
unlik area overcom weak core busi disappoint
quarter book maintain mp rate continu believ major top-lin growth
acquir asset end-market slow possibl even shrink number
breadth adjust also continu high view pt declin
maintain mp rate cautiou view
guid maintain low-end prior rang
complic sale process netsmart weigh result make deal uncertain
continu book weak blame roi driven sale netsmart
revenu adjust non-gaap mm ep adjust street-compar basi ex
fa expens non-cash expens
eye upcom decis unbundl exparel asc pt
 methodolog dcf use wacc termin growth rate
bottom line believ near-term exparel trajectori continu look good expand
ambulatori surgic center opportun two month away assum
propos get approv soon exparel grew y/i even show growth q/q nerv
block opportun continu take shape op collabor provid tailwind
rais exparel sale estim due factor estim within
manag revis guidanc rang top propos
unbundl asc begin januari could drive upsid estim
final decis impend rais price target slightli reflect
improv outlook exparel near-term growth opportun exparel continu look
promis still believ exparel growth outer year could pressur due competit
manag provid preliminari color potenti impact exparel unbundl set
chang model
recap momentum build solid growth instrument
sale dcf wacc
bottom line remain op given compani revenu compound-annual-growth-rate
profil deriv revenu biopharma custom
will pay premium improv sensit report anoth solid
quarter deliv growth y/i remov one-tim charg associ biomerieux
collabor termin quarter consum growth vs instrument deliv
y/i growth believ backlog build qrtx result appear set
acceler util high neurolog oncolog also start pick
quarter growth balanc across pharma academ pharma deliv
premium custom includ biopharma/biotech custom valu simoa drive signific
consum volum among valu simoa technolog biopharma biotech
develop drug assay screen studi companion diagnost cdx current
deriv revenu custom also drive signific test volum
sensit come higher price biopharma cro custom less price sensit product
high relev translat research project clinic trial effort
qtrx sensit simoa platform remain key success
prime time nih fund neurolog alzheim research benefit disproportion
revenu non-gaap oper ep present ep number sinc
share count ipo
base dcf thru discount rate termin growth rate
bottom line radiu tymlo sale beat sale cash guidanc announc
revers financ overhang driven reduct share price last quarter
phase updat lead pipelin asset elacestr mix posit expans earlier
treatment line doubl address patient popul compens later
vs previous expect approv date radiu also spend less expect
help reduc model impact delay elacestr compar consensu
expect given elacestr initi concret timelin increas probabl
success elacestr line compar phase asset coverag
univers time trend remain posit tymlo expect uncertainti
emerg launch gener forteo approach also lower expens
long-term price target increas base higher valu elacestr
reiter outperform rate radiu stock suffer appar financ overhang
uncertainti key pipelin asset abaloparatid patch elacestr clarif
revenu cash burn clinic develop trajectori stabil stock valuat
investor sentiment
ep exclud stock option expens amort intang
recap base busi lumpi pipelin expand pt
bottom line market close held earn call report sale
repres increment y/i growth although expect due slower growth
bile acid product remaind compani rare diseas pipelin remain track
third pivot trial set initi evalu lead asset sparsentan iga
nephropathi igan ad program model po rais price
target accordingli end cash equival believ
allow compani support develop promis portfolio asset potenti enabl
addit in-licens opportun reiter op pt
sparsentan demonstr efficaci similar rare form kidney diseas support enthusiasm
rtrx effort igan
long-term efficaci data tighten align key stakehold rare kidney diseas
long-await complet enrol fort studi sight anticip
commenc poc studi data anticip
sale lower anticip annual revenu guidanc adjust result
chang model
revenu million
bottom line report solid quarter report result line rais guidanc
provid sept i-day link consensu expect report revenu
compar consensu adjust ebitda mm vs consensu
mm provid guidanc rais revenu ep guidanc slightli manag
host confer call afternoon et expect call focu
sale cycl focu sell larg nation plan medicar advantag strategi
price given recent rule link advanc medic integr cross-sal execut
gross margin degrad ebitda expans addit expect attent given
revenu mm essenti line consensu increas yoy
rais revenu ep guidanc midpoint respect
management also provid guidanc ahead consensu
manag host confer call pm et today
focu call like
save copaxon drive nt beat ajovi remain wild card
ev/ebitda multipl ebitda
bottom line continu look pois out-perform although remain market
perform given uncertainti around ajovi ramp gener growth teva declin
week ajovi approv earn releas overli surpris
posit stock move teva continu put number copaxon franchis
cost-cut initi continu come faster-than-expect said maintain market
perform rate given follow continu uncertainti ajovi still clear home run
initi physician feedback patient adopt quarterli dose look promis market
shape competit could call bigger rebat anticip cost-cut
far faster-than-expect see potenti meaning greater save
manag guidanc still see north american busi declin high
singl digit continu pressur copaxon addit gener competit us
gener busi reiter mp pt
chang model
initi uptak ajovi quarterli dose surpris howev payer coverag rebat level
still key unknown variabl stage
us copaxon still hold strong believ franchis outperform manag
manag note start see stabil us gener although time would
optimist interpret stabil rate declin
bodi note
base rebound neotract turn organ y/i
ep
bottom line reiter op follow organ revenue growth beat follow
higher confid y/i revenue acceler territori mid-teen ep
growth prospect beyond believ enough levers/driv period
drive hsd revenu growth deliv mid-teen ep growth
margin improv -- -a better profil mani peer well see upsid potenti
out-year forecast consid model contempl meaning benefits/contribut
repla tfx lyophil freeze-dri fresh frozen plasma product manta devic acquir
essenti medic acquisit pend pma approv neotract sale
addt restructur initi addt pt stay assum trade
turn price-to-earnings premium peer group forward price-to-earnings appli vs current
price-to-earnings ep slightli lower due higher fx headwind assumpt impact
get us pt
organ cc day adj growth acceler beat expect op margin in-lin ep
beat mostli help tax benefit
management reiter full-year org cc revenue outlook report basi fx result came slightli
lower report revenue margin outlook ep guidanc still increas lower int exp tax assumpt
confid increas reiter full year y/i org cc growth
neotract revenue beat consensu slightli post solid y/i growth increas confid
remain growth engin compani
report revenue ep model assumpt updat primarili reflect bigger fx headwind
step invest partial off-set lower tax interest expens
revenu mm ep present note valuat base pf ep
surpris driven european rev sustain focu shift
bottom line tesaro report world-wide zejula revenu beat consensu
estim driven strong uptak europ improv price per prescript
us importantli compani rais full-year guidanc indic expect continu
sale growth face increas competit despit on-going challeng grow
parp adopt us see zejula surpris beat rais particularli light low
expect follow competitor clovi mp result posit catalyst tsro
share especi sinc fundament driver european growth appear sustain
near intermedi term follow long-term competit advantag front-lin
ovarian set also see focu shift immuno-therapi io pipelin catalyst
includ data present upcom societi immunotherapi
cancer meet novemb expect tsro share strong exit last night
call reiter op rate
zejula beat rais driven strong uptak europ improv us price
european demand could sustain zejula growth near intermedi term given competit
advantag market
cautious optimist given high level investor skeptic
tesaro believ acceler approv path refractori nsclc possibl
updat model follow earn pt remain
deliv expect potenti stronger pickup
outperform market cap price price target methodolog average
dcf ev/ sale
bottom line remain outperform biosystem base upon expand opportun
result fda clearanc lift compani estim market opportun
continu believ clearanc allow penetr
per ttoo bacteri sepsi market immedi entri point hospit emerg
depart ed associ microbiolog lab market need acut
ttoo report revenu almost equal split research revenu product
ttoo also deliv instrument instal almost believ compani
like exceed placement guid alreadi deliv believ stori
remain track hope see acceler placement pull-through
beyond reiter pt
propos expect drive futur busi
continu see upsid expans
emerg depart ed opportun acut open new market
revenu ep present
luspatercept abstract confirm robust md effect less impress
bottom line morn abstract american societi hematolog meet
becam avail on-line show data phase luspatercept studi myelodysplast
syndrom md beta-thalassemia previous disclos top-line press
releas celgen op /acceleron op medalist md trial luspatercept result
rate red blood cell transfus independ rbc-ti versu placebo-tr patient
believ beta-th studi luspatercept-tr subject reduct transfus
burden versu receiv placebo result increment posit confirmatori
luspatercept indic make regulatori approv seem near certainti would make
sens us acceleron celgen stock would react posit disclosur sinc
regulatori approv import asset appear near certainti stage
encourag learn luspatercept phase data medalist highlight one
top six clinic result select plenari present meet decemb
bottom line today poster abstract made avail annual meet websit
discuss mani note publish day today one
biggest concern investor alexion risk pose roch program
activ clinic develop pnh complement mediat condit
subject poster session monday decemb roth et al
bottom line data phase augment studi relapsed/refractori follicular lymphoma
fl detail on-line abstract publish american societi hematolog
websit morn link show substanti benefit revlimid-rituximab
combin rituximab alon addit progress free surviv benefit
appear superior expect immunochemotherapi combin second line
follicular lymphoma set base histor result believ result one reason
celgen stock outperform today estim increment revenu opportun
revlimid follicular lymphoma much per year
abstract show strong symptom relief advanc sm import
bottom line morn abstract american societi hematolog meet
becam avail on-line includ data oral present avapritinib advanc
system mastocytosi sm show meaning symptom relief patient on-going
explor trial see symptomat improv key driver uptak complianc
avapritinib especi patient indol diseas could expand
opportun beyond current forecast believ investor read
symptom relief seen advanc sm replic indol sm patient
primari driver clinic benefit current attribut minim valu indol sm continu
view potenti sourc upsid estim
increment new data disclos abstract present
bottom line abstract american societi hematolog publish
morn among publish abstract data arql phase dose-escal studi arq
revers inhibitor wild type mutant btk overal abstract provid
increment new inform vs data previous present in-lin expect given
abstract submiss deadlin data abstract continu focu encourag
safeti profil preliminari sign activ seen dose expect sub-therapeut although
pharmacolog data dose cohort new patient achiev pbtk knockdown
arql last provid updat european hematolog associ eha june expect
meaning updat actual present base past manag guidanc link
notabl competitor data snss vecabrutinib also revers btk inhibitor also present
abstract recal arql clinic stage biotech compani develop small molecul
precis medicin space treat cancer rare diseas within arql pipelin continu
view arq excit sourc signific potenti upsid stock indic
arq could play role chronic lymphocyt leukemia cll remain dynam
competit medacorp kol check highlight potenti arq link see potenti
long-term appreci arq becom de-risk clinic updat next
clinic updat expect reiter op
data abstract still earli multipl readout
bottom line abstract american societi hematolog publish
morn among publish abstract initi data asln phase iia studi
dhodh inhibitor relapsed/refractori r/r acut myeloid leukemia aml overal abstract
provid earli signal clinic activ patient treat cut-off date
abstract data first disclos competitor dhodh
space includ bayer current phase studi myeloid malign agio
mp ind submit repres upsid current estim asln
oncology-focus biopharmaceut compani base singapor develop therapeut global
market compani lead program varlitinib revers small molecul pan-human epiderm
growth factor receptor pan-her inhibitor target recal varlitinib
origin licens arri nr complet five phase studi rang
solid tumor asln develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer varlitinib clinic data gener date asln
arri demonstr activ want see clinic mechanist valid
varlitinib given biliari tract cancer histor difficult space drug develop
mechanist advantag varlitinib pan-her inhibitor remain unclear given implic
target remain poorli understood overal posit asln asia-focus
develop strategi experi manag team would want see clinic
mechanist valid varlitinib catalyst-rich reiter mp
abstract encourag investor focu remain forward-i
bottom line abstract american societi hematolog publish
morn among publish abstract data two phase program
target antibody-drug conjug partner
op abstract highlight efficaci updat previous present
phase data abstract offer first look efficaci phase
studi sever earli dataset expect link note abstract highlight
earli efficaci present flotetuzumab among sever updat
present earli data disclos abstract encourag believ
bulk investor focu remain lead asset mirvetuximab soravtansin antibody-drug conjug
target folat receptor fr upcom top-lin data phase forward-
studi platinum-resist ovarian cancer proc recent conduct deep-div
medacorp key opinion leader kol address multipl controversi ahead top-lin readout
link -- foundat frnchise preview forward-i data overal continu
believ forward-i studi like posit base compel monotherapi data
present date although valid concern investor signific downsid risk
stock studi fail reiter op
multipl present full sadal data confer
bottom line abstract american societi hematolog publish
morn among publish abstract data phase ii sadal studi evalu
selinexor diffus larg b-cell lymphoma dlbcl overal abstract provid littl new inform
although confirm sadal data would present specif abstract
commit present full studi result includ longer follow durat respons dor
overal surviv os origin interim analysi abstract last provid
updat european hematolog associ eha meet recal sadal phase
iib studi expect enrol total relapsed/refractori dlbcl patient
later line set manag previous guid top-lin data press
releas disclos top-lin data includ data patient treat dose
previous present eha meet well addit patient recruit treat
dose overal view selinexor activ drug could place dlbcl
ptcl data abstract still earli present
bottom line abstract american societi hematolog publish
morn among publish abstract tipifarnib phase ii biomarker-enrich data
peripher t-cell lymphoma look identifi valid biomark prospect
basi tipifarnib hematolog malign view opportun tipifarnib outsid solid tumor
overlook import driver upsid vs street expect overal data abstract
still earli data cut-off date abstract last provid updat
studi expect meaning updat actual present
base past manag guidanc link continu view well-posit long term
manag team execut well tipifarnib develop strategi recal
licens world-wide right tipifarnib indic virolog janssen op
previous evalu tipifarnib broadli across variou hematolog solid tumor limit success
believ precis medicin approach develop tipifarnib biomarker-defin patient
offer opportun improv past effort base review literatur medacorp kol
bottom line abstract american societi hematolog publish
morn among publish abstract data phase studi flotetuzumab
bispecif acut myeloid leukemia aml overal data abstract indic
moder drop-off respons rate previous publish data although small patient
number object respons rate orr patient vs patient
complet respons rate crr patient vs patient competitor abstract data two
program op bispecif partner nv
op antibody-drug conjug partner
op also publish morn data highlight crr data
highlight crr overal view bispecif antibodi promis drug
class one broadest deepest pipelin proprietari partner bispecif
antibodi clinic develop evolv bispecif landscap remain competit
multipl program develop maintain favor view ahead multipl
clinic catalyst expect
abstract highlight earli efficaci present
bottom line abstract american societi hematolog publish
morn among publish abstract first publish data plug play next-
gener bispecif platform phase studi bispecif partner
novarti patient acut myeloid leukemia aml abstract highlight earli respons
patient two highest dose level studi date indic complet respons rate
crr competitor abstract data two program
op flotetuzumab op also present today data
flotetuzumab bispecif demonstr crr data
antibodi drug conjug partner demonstr crr
clinic stage biotechnolog compani develop engin antibodi treat
autoimmun allerg diseas cancer indic plug-and-play antibodi
platform gener deep pipelin consist advanc stage proprietari program
earli stage partner proprietari bispecif antibodi key valu driver lead
proprietari program enter phase studi orphan indic
diseas rd support promis phase ii data addit deep pipelin
earli stage bispecif antibodi program expect first clinic data american
societi hematolog view bispecif antibodi promis drug class
bispecif platform import long-term valu driver compani potenti
sourc busi develop opportun futur also enter numer
technolog licens agreement repres valid platform potenti increment
near-term cash flow compani reiter op
tibsovo launch encourag posit develop regulatori
thru discount rate
bottom line agio report tibsovo net sale ahead estim
first partial quarter launch manag comment key commerci dynam
encourag agio also disclos posit updat develop program notabl
frontlin aml acut myeloid leukemia agio intend submit snda
tibsovo first-lin aml patient fit receiv treatment end januari
follow discuss fda agio also chang primari endpoint phase
agil trial tibsovo vidaza unfit aml patient event free surviv ef enabl
reduc enrol expect complet net result chang potenti
acceler tibsovo use patient elig receiv chemo see
acceler regulatori timelin posit data contain abstract releas
morn suggest potenti shorter durat therapi patient unabl receiv chemo
hypomethyl agent hma evalu impact forecast
reimburs chang acceler shift value-
marri payor provid data verita report interest athn
set upsid beyond rais ep pt
 methodolog ep
strateg pe bidder emerg sale like
recap pipelin track tripl meet
quarter retent volum price
 methodolog pt deriv rang dcf valuat deriv
base case upsid scenario supplement ev/fcf ev/ebitda analys
superl sale china valid emerg market like boost
strong rais healthcar global supp see margin
small china studi safeti signal probabl storm teacup
recap pbc still path regener rev nash interim data
analysi discount rate termin growth rate
china robot quota final mean system/procedur upsid out-
blow-out stun magnitud turnaround
recap solid growth continu genoptix integr pt
recap add optim candid push first ind
 methodolog ev/sal multipl appli sale
 med-surg market remain pressur turn-around need turn-
sell-off appear profit take offer substanti growth
price-to-earnings ep
modest rais in-lin revenu driven tax rate
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi link
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
given superl clinic data present date expect fda approv
nov link note
larotrectinib loxo lead agent potent specif pan-trk tropomyosin receptor
kinas inhibitor combat basket tumor includ lung breast colon
trk biomark individu estim us
larotrectinib next-gen trk inhibitor partner bayer hold
ex-u commerci right pay loxo tier double-digit royalti ex-u sale
loxo bayer co-develop us cost profit split loxo
receiv up-front payment potenti receiv mileston payment
us ou larotrectinib
project combin larotrectinib peak probability-of-success
adjust sale us europ larotrectinib eu
submit august
dec epo patent challeng relat rubraca ovarian prostat
dec european patent offic epo hear oral argument render
opinion patent challeng camsyl salt patent provid ip protect
eu drug rubraca
challeng file divis sandoz anonym parti contend
epo patent recent grant clovi novel -- argument preliminari
opinion agre cite prior art exist applic file
medacorp specialist review preliminari opinion render april felt
opposit strong argument could result narrow patent claim
claim narrow eu could make invent step difficult
uphold unexpect product attribut may compar broadli potenti
open door prior art consid
view eu patent challeng relev impact potenti
takeout option potenti read-through us exclus
composit matter patent expir without addit patent support drug
intellectu properti ip runway relev us patent howev like
hotli debat even dec goe poorli
sourc leerink research compani inform factset price prior day
fda adcom joint psychopharmacolog drug drug safeti risk
fda adcom vaccin relat biolog product
pdufa revefenacin lama copd
fda adcom joint anesthet analges drug product drug safeti
pdufa roxicodon abuse-deterr formul immediate-releas single-
north carolina dhh award rfp transit medicaid program manag
may texa hhsc award rfp star plu medicaid manag care program
american colleg prosthodontist
associ molecular patholog
american associ scientist
societi immunotherapi cancer adap imdz iph tril
intern confer societi medic innov technolog
intern societi traumat stress studi
american associ studi liver diseas
american societi cytopatholog
societi neuro-oncolog
american colleg allergi asthma immunolog
intern societi pediatr oncolog
radiolog societi north america
life scienc biolog engin confer
societi urolog oncolog
intern feder adipos therapeut scienc
asian pacif societi respirolog
american societi hematolog present pst -arql ad
sadal studi abstract session
abstract paraxysm nocturn hemoglobinuria
manag end sell season
univers coverag
calendar event
model model athn esrx recent
updat pleas contact leerink repres wish review
biopharma preview gener pain women health anti-infect
 biotech earn unlik offer much excit best
hcit distribut preview price pressur continu gener
medic suppli devic individu co preview cardio large-cap diversifi
medic suppli devic individu co preview ortho supplies/cap equipment/
payor servic posit catalyst
 disappoint ctad fade prospect ban bace market
-- flash data thin unconvinc benefit limit carrier
 ctad disclosur unlik bolster amyloid outlook market perform
